← Back to Home

Adding immunotherapy before and after head and neck cancer surgery improves event-free survival in phase 2 trial

The randomized CAMORAL trial shows that a perioperative strategy combining camrelizumab with chemotherapy can improve two-year event-free survival in patients with resectable head and neck cancer; however, a higher toxicity burden and limited follow-up also define the limits of these findings.

By SURL BioNews

For patients with locally advanced head and neck cancer, being eligible for surgery does not mean the risk of recurrence disappears. Controlling potentially remaining cancer cells beyond tumor removal is an important treatment challenge. The phase 2 randomized CAMORAL trial, published November 12 in JAMA Oncology, showed that incorporating the immunotherapy camrelizumab before and after surgery, combined with chemotherapy before surgery, could improve event-free survival, adding clinical evidence for this strategy.

The study was conducted at four hospitals in China and enrolled 125 previously untreated patients with resectable stage III to IVB head and neck squamous cell carcinoma. The 63 patients assigned to the experimental group received two cycles of camrelizumab and chemotherapy, followed by surgery, risk-based adjuvant therapy, and continued camrelizumab; the remaining 62 patients underwent surgery first, followed by radiotherapy or concurrent chemoradiotherapy according to pathological risk. This comparison evaluated the entire treatment strategy and cannot isolate the contributions of preoperative or postoperative drug treatment.

After a median follow-up of 24.6 months, two-year event-free survival was 77.8% in the experimental group and 46.1% in the control group, a difference of 31.7 percentage points; the hazard ratio was 0.34, with a 95% confidence interval of 0.17 to 0.68. This endpoint includes events such as disease progression precluding curative surgery, postoperative recurrence or metastasis, a second primary cancer, and death. It is not equivalent to a cure rate.

An abstract from the same trial previously presented at the 2025 European Society for Medical Oncology (ESMO) Congress also showed a consistent direction of benefit: two-year overall survival was 92.0% in the experimental group and 69.1% in the control group. In the experimental group, 47.6% achieved a major pathological response and 25.4% achieved a pathological complete response, meaning no residual viable invasive cancer was found in the resected primary tumor and sampled lymph nodes. These results support further research, but a pathological response still cannot guarantee that recurrence will not occur later.

The improvement in efficacy came with a higher toxicity burden. In the journal report, grade 3 or higher treatment-emergent adverse events occurred in 79.4% of the experimental group and 56.5% of the control group; decreases in white blood cells, lymphocytes, and neutrophils were more common in the experimental group. The study authors described the overall toxicity as manageable, but this does not mean treatment is easy or that adding medication comes without a cost.

Definitions require particular attention when reading safety data from different versions of the report. The earlier ESMO abstract reported grade 3 or higher “treatment-related” adverse events of 58.7% and 21.0%, which are not the same measure as the “treatment-emergent” adverse events used in the journal article: the former involves investigators’ assessment of causality, while the latter has a broader scope. The two sets of figures cannot be directly treated as evidence of an increase or decrease in toxicity.

Camrelizumab is an antibody that blocks the PD-1 immune checkpoint. Moving its use to before surgery aims to activate anticancer immunity while the tumor is still present, then sustain control through postoperative treatment. However, CAMORAL had an open-label design and a limited sample size, and 82.4% of patients had primary tumors in the oral cavity, so the results may not be directly generalizable to all head and neck cancer populations. Five-year results are not yet mature, and larger phase 3 trials are still needed to confirm the long-term benefits and risks before the role of this strategy in clinical treatment can be determined.

References

  1. JAMA Oncology
  2. European Society for Medical Oncology